(Q39876916)

English

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

based on heuristic

inferred from title

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

author name string

Samad Amini-Bavil-Olyaee

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Ulf Herbers

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Tom Luedde

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Christian Trautwein

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Frank Tacke

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

language of work or name

0 references

publication date

1 April 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1158-1165

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Treatment of chronic hepatitis B and the implications of viral resistance to therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance--implications for novel antiviral strategies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Hepatitis B goes globe: Telbivudine as a new treatment option

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

CREB/PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Evidence that the 5'-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

The hepatitis B virus and common mutants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Role of tenofovir in the treatment of chronic HBV infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

21 January 2018

Relevance of hepatitis B core gene deletions in patients after kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

7 January 2021

based on heuristic

inferred from DOI database lookup

The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

7 January 2021

based on heuristic

inferred from DOI database lookup

Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22790

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.22790

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39876916&oldid=2091930013"